Clinical Trials Logo

Clinical Trial Summary

Prolactinoma, one of the most common pituitary adenomas, is an adenoma that causes excessive prolactin (PRL) secretion. An increase in prolactin level can cause weakness, decrease in muscle mass and fatigue. It is not known in detail to what extent it affects quality of life, functional exercise capacity, cardiovascular disease risk factors, physical activity level, fatigue and sleep quality in prolactinoma patients. It is aimed to compare how much exercise capacity, physical activity level, sleep quality, perception of fatigue and quality of life of prolactinoma patients are affected compared to healthy individuals and to examine the factors associated with exercise capacity in prolactinoma patients.


Clinical Trial Description

Prolactinoma is a pituitary adenoma caused by excessive prolactin secretion. More than 70% of patients are women. Many physiological conditions such as pregnancy, breastfeeding, breast stimulation, stress, exercise and sleep can also increase PRL levels. Prolactin can affect arterial stiffness and blood pressure and cause atherosclerosis in early menopause. In addition to these, it has negative effects on heart rhythm and heart failure. In addition to these clinical findings, the extent to which body weight gain and fatigue symptoms affect quality of life, functional exercise capacity, cardiovascular disease risk factors, physical activity level, fatigue and sleep quality in prolactinoma patients is not known in detail. There are very few studies on these subjects. Height, weight, waist circumference, hip circumference will be measured for all participants, waist-hip ratio and body mass index (BMI) will be calculated. The exercise capacity levels of the individuals who will participate in the study will be evaluated with the 6 Minute Walk Test (6MWT). Risk factors knowledge levels about cardiovascular diseases will be evaluated with Cardiovascular Diseases Risk Factors Knowledge Level (CARRIF-BD) Scale. Physical activity level will be evaluated with the Turkish version of the short form of the International Physical Activity Questionnaire (IPAQ). The Pittsburgh Sleep Quality Index (PUKI) was used to evaluate sleep quality. Fatigue assessment will be evaluated with the Multidimensional Fatigue Rating Scale. quality of life will be evaluated with the SF-36 short form. Measurement of knee extensor muscle strength will be made with a portable digital dynamometer (JTECH, Medical Commander Powertrack II, Midvale, USA). Peripheral muscle endurance assessment will be done by bilateral squat test. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05236829
Study type Observational
Source Hacettepe University
Contact
Status Completed
Phase
Start date June 16, 2021
Completion date October 15, 2022

See also
  Status Clinical Trial Phase
Completed NCT03038308 - Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Phase 1/Phase 2
Not yet recruiting NCT03400865 - Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas N/A
Completed NCT00481299 - Insulin Resistance in Women With Prolactinoma N/A
Terminated NCT04106531 - Validation of a Quality of Life Metric "Prolac-10"
Completed NCT01504399 - Rhinological Outcomes in Endonasal Pituitary Surgery
Recruiting NCT03474601 - Seoul National University Pituitary Disease Cohort Study
Recruiting NCT04107480 - PRolaCT - Three Prolactinoma RCTs Phase 4
Completed NCT00697814 - Clomiphene in Males With Prolactinomas and Persistent Hypogonadism Phase 2
Recruiting NCT03353025 - Study on Therapy of Non-invasive Prolactinoma N/A
Recruiting NCT03457389 - Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma N/A
Recruiting NCT01775332 - Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools N/A
Not yet recruiting NCT03717454 - Dopamine D2 Receptors(D2R) Imaging in Prolactinomas N/A
Recruiting NCT00001595 - An Investigation of Pituitary Tumors and Related Hypothalmic Disorders